Biotech's surge pushes Bay Area companies — including a Covid drug hopeful — toward collective $1 billion in fresh funds

Three pending Bay Area biotech IPOs and follow-on offerings from four other drug makers could collectively raise more than $1.1 billion, highlighting biotech's latest Wall Street resurgence amid hope for new cancer treatments and drugs and vaccines targeting Covid-19. Annexon Inc., which said last week that it raised $100 million, marked its place for an initial public offering of $100 million filing as Nurix Therapeutics Inc. declared its intentions for a $100 million IPO and Nkarta Inc. detailed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news